Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Amortization of Deferred Charges (2022 - 2023)

Century Therapeutics (IPSC) has disclosed Amortization of Deferred Charges for 2 consecutive years, with $38000.0 as the latest value for Q2 2023.

  • Quarterly Amortization of Deferred Charges fell 50.0% to $38000.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $94000.0 through Dec 2023, down 68.46% year-over-year, with the annual reading at $94000.0 for FY2023, 68.56% down from the prior year.
  • Amortization of Deferred Charges for Q2 2023 was $38000.0 at Century Therapeutics, down from $56000.0 in the prior quarter.
  • The five-year high for Amortization of Deferred Charges was $77000.0 in Q3 2022, with the low at $38000.0 in Q2 2023.